Glucotrack, Inc. GCTK
and "Glucotrack" refer to Glucotrack, Inc., a Delaware corporation.
of an implantable continuous blood glucose monitor ("CBGM") for persons with Type 1 diabetes and Type 2 diabetes using insulin
or at risk for hypoglycemia (the "Glucotrack CBGM").
diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive)
Last close
0.40
2026-10-23
Market cap
$4.3M
2026-06-30 share count
52-week range
0.37 - 112.50
Valuation FY2025 figures against the last close
P/S—
P/E0.0x
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS31.22
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $208.0K | $43.5K | $589.5K | $611.7K |
| R&D | $9.8M | $9.5M | $4.7M | $2.0M | $1.8M | $1.5M | $1.6M | $3.0M | $3.2M | $2.9M |
| SG&A | $6.3M | $5.0M | $2.3M | $2.5M | $2.1M | $415.0K | $1.5M | $2.5M | $6.4M | $1.1M |
| Total operating expenses | $16.1M | $14.5M | $7.1M | $4.4M | $4.0M | $3.1M | $3.7M | $6.6M | $11.2M | $6.3M |
| Operating income | -$16.1M | -$14.5M | -$7.1M | -$4.4M | -$4.0M | -$3.1M | $3.5M | -$6.5M | $10.6M | -$5.7M |
| Interest expense | — | $44.0K | — | — | — | — | $43 | $18.3K | $24.4K | $16.2K |
| Pre-tax income | — | — | — | — | — | -$2.7M | -$3.5M | -$6.7M | -$10.3M | -$5.4M |
| Net income | -$19.4M | -$22.6M | -$7.1M | -$4.4M | -$4.1M | -$2.7M | $3.5M | -$6.7M | $10.3M | -$5.4M |
| EPS, basic | 31.22 | 4,106.00 | 34.18 | 0.29 | 0.26 | -0.02 | -0.02 | -4.74 | -1.87 | -1.08 |
| EPS, diluted | 31.22 | 4,106.00 | 34.18 | 0.29 | 0.26 | 0.19 | -0.02 | -4.74 | -1.87 | -1.08 |
| Shares, diluted (wtd. avg.) | 621,094 | 5,503 | 207,603 | 15.5M | 15.5M | 196.0M | 154.9M | 8.4M | 6.3M | 5.8M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.4M | $5.6M | $4.5M | $2.3M | $6.1M | $9.9M | $476.0K | $150.0K | $53.8K | $184.5K |
| Receivables | — | — | — | — | — | $66.0K | $70.0K | $22.8K | $121.8K | $92.1K |
| Inventory | — | — | — | — | — | $284.0K | $184.0K | $171.0K | $957.3K | $1.4M |
| Total current assets | $7.7M | $5.8M | $4.9M | $2.4M | $6.1M | $10.2M | $718.0K | $314.1K | $1.2M | $2.0M |
| Property, plant and equipment | $138.0K | $95.0K | $27.0K | $40.0K | $69.0K | $149.0K | $134.0K | $149.8K | $216.7K | $240.5K |
| Total assets | $7.8M | $5.9M | $4.9M | $2.4M | $6.3M | $10.6M | $1.1M | $688.2K | $1.7M | $2.5M |
| Accounts payable | $1.3M | $992.0K | $839.0K | $672.0K | $631.0K | $869.0K | $1.5M | $2.1M | $2.4M | $1.6M |
| Total current liabilities | $4.8M | $1.3M | $1.5M | $1.0M | $883.0K | $1.3M | $2.3M | $3.2M | $3.7M | $2.3M |
| Total liabilities | $5.0M | $18.9M | $1.7M | $1.2M | $1.1M | $1.6M | $2.5M | $3.6M | $4.8M | $3.4M |
| Retained earnings | -$151.8M | -$132.4M | -$109.9M | -$101.9M | -$97.5M | -$93.4M | -$90.7M | -$87.2M | -$47.4M | -$35.6M |
| Total equity | $2.8M | -$13.0M | $3.2M | $1.2M | $5.2M | $9.0M | -$1.4M | -$2.9M | -$16.6M | -$10.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.2M | -$12.5M | -$6.6M | -$3.7M | -$3.8M | -$3.5M | -$3.9M | -$4.9M | -$5.9M | -$5.3M |
| Depreciation and amortisation | $42.0K | $36.0K | $13.0K | $23.0K | $42.0K | $47.0K | $51.0K | $58.8K | $67.9K | $59.6K |
| Stock-based compensation | $211.0K | $173.0K | $281.0K | $439.0K | $223.0K | $22.0K | $356.0K | $705.2K | $2.7M | $70.2K |
| Capital expenditure | $96.0K | $104.0K | — | $1.0K | $5.0K | $53.0K | $23.0K | $5.4K | $19.5K | $76.5K |
| Investing cash flow | -$96.0K | -$104.0K | — | $1.0K | -$1.0K | -$53.0K | -$23.0K | -$5.4K | -$19.5K | -$76.5K |
| Financing cash flow | $17.0M | $13.7M | $8.7M | — | — | $13.0M | $4.2M | $5.0M | $5.8M | $4.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-033763.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $611.7K | $589.5K | $43.5K | $208.0K | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$5.4M | $10.3M | -$6.7M | $3.5M | -$2.7M | -$4.1M | -$4.4M | -$7.1M | -$22.6M | -$19.4M |
Recent filings and events
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Item 3.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |